Using recombinant proteins from Lutzomyia longipalpis saliva to estimate human vector exposure in visceral leishmaniasis endemic areas

dc.creatorSouza, Ana Paula Almeida de
dc.creatorAndrade, Bruno de Bezerril
dc.creatorAquino, Dorlene Maria Cardoso de
dc.creatorEntringer, Petter F
dc.creatorMiranda, José Carlos
dc.creatorAlcantara, Ruan
dc.creatorRuiz, Daniel
dc.creatorSoto, Manuel
dc.creatorTeixeira, Clarissa Romero
dc.creatorValenzuela, Jesus G
dc.creatorOliveira, Camila Indiani de
dc.creatorBrodskyn, Claudia Ida
dc.creatorBarral Netto, Manoel
dc.creatorBarral, Aldina Maria Prado
dc.date2011-04-06T14:19:25Z
dc.date2011-04-06T14:19:25Z
dc.date2010
dc.date.accessioned2023-09-26T21:04:24Z
dc.date.available2023-09-26T21:04:24Z
dc.identifierSOUZA, A. P. et al. Using recombinant proteins from Lutzomyia longipalpis saliva to estimate human vector exposure in visceral leishmaniasis endemic areas. PLoS Neglected Tropical Diseases, v.4, n.3, p.e649, 2010.
dc.identifier1935-2735
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/1871
dc.identifier10.1371/journal.pntd.0000649
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8868701
dc.descriptionBACKGROUND: Leishmania is transmitted by female sand flies and deposited together with saliva, which contains a vast repertoire of pharmacologically active molecules that contribute to the establishment of the infection. The exposure to vector saliva induces an immune response against its components that can be used as a marker of exposure to the vector. Performing large-scale serological studies to detect vector exposure has been limited by the difficulty in obtaining sand fly saliva. Here, we validate the use of two sand fly salivary recombinant proteins as markers for vector exposure. METHODOLOGY/PRINCIPAL FINDINGS: ELISA was used to screen human sera, collected in an area endemic for visceral leishmaniasis, against the salivary gland sonicate (SGS) or two recombinant proteins (rLJM11 and rLJM17) from Lutzomyia longipalpis saliva. Antibody levels before and after SGS seroconversion (n = 26) were compared using the Wilcoxon signed rank paired test. Human sera from an area endemic for VL which recognize Lu. longipalpis saliva in ELISA also recognize a combination of rLJM17 and rLJM11. We then extended the analysis to include 40 sera from individuals who were seropositive and 40 seronegative to Lu. longipalpis SGS. Each recombinant protein was able to detect anti-saliva seroconversion, whereas the two proteins combined increased the detection significantly. Additionally, we evaluated the specificity of the anti-Lu. longipalpis response by testing 40 sera positive to Lutzomyia intermedia SGS, and very limited (2/40) cross-reactivity was observed. Receiver-operator characteristics (ROC) curve analysis was used to identify the effectiveness of these proteins for the prediction of anti-SGS positivity. These ROC curves evidenced the superior performance of rLJM17+rLJM11. Predicted threshold levels were confirmed for rLJM17+rLJM11 using a large panel of 1,077 serum samples. CONCLUSION: Our results show the possibility of substituting Lu. longipalpis SGS for two recombinant proteins, LJM17 and LJM11, in order to probe for vector exposure in individuals residing in endemic areas.
dc.formatapplication/pdf
dc.languageeng
dc.rightsopen access
dc.subjectLeishmaniose visceral
dc.subjectELISA/MT
dc.subjectProteínas
dc.subjectPsychodidae
dc.subjectSaliva/IM
dc.titleUsing recombinant proteins from Lutzomyia longipalpis saliva to estimate human vector exposure in visceral leishmaniasis endemic areas
dc.typeArticle


Este ítem pertenece a la siguiente institución